Esperion Therapeutics, Inc. (NASDAQ:ESPR) to Post Q1 2026 Earnings of $0.40 Per Share, Zacks Research Forecasts

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Analysts at Zacks Research dropped their Q1 2026 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research note issued to investors on Monday, May 6th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will post earnings per share of $0.40 for the quarter, down from their previous forecast of $0.51. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.68) per share.

ESPR has been the subject of several other research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 price objective on shares of Esperion Therapeutics in a report on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a report on Monday, March 25th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $9.33.

Esperion Therapeutics Stock Up 11.8 %

Shares of ESPR stock opened at $2.37 on Tuesday. The company has a market capitalization of $448.88 million, a P/E ratio of -1.12 and a beta of 0.89. Esperion Therapeutics has a 12-month low of $0.70 and a 12-month high of $3.40. The firm has a 50-day moving average price of $2.32 and a 200 day moving average price of $2.07.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.03. The company had revenue of $32.25 million for the quarter, compared to analyst estimates of $26.84 million. During the same quarter in the prior year, the company earned ($0.76) earnings per share.

Institutional Trading of Esperion Therapeutics

Hedge funds have recently modified their holdings of the stock. Herbst Group LLC acquired a new position in Esperion Therapeutics during the 1st quarter worth $28,000. Chicago Partners Investment Group LLC acquired a new position in shares of Esperion Therapeutics during the third quarter valued at $29,000. Private Portfolio Partners LLC bought a new position in Esperion Therapeutics in the fourth quarter valued at about $30,000. CVI Holdings LLC acquired a new stake in Esperion Therapeutics in the first quarter worth about $37,000. Finally, Simplicity Wealth LLC acquired a new stake in Esperion Therapeutics in the first quarter worth about $44,000. 47.39% of the stock is owned by institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.